Clinical Report: Digital Patching with CureSight for Amblyopia Treatment

Overview

CureSight, a digital amblyopia treatment platform approved by the FDA, improves visual and stereo acuity in children aged 4 to 9 with anisometropic and mild strabismic amblyopia. The device uses eye-tracking and selective blurring of the dominant eye to encourage use of the amblyopic eye, showing promising improvements in visual acuity and binocular function.

Background

Amblyopia, commonly known as lazy eye, is a neurodevelopmental vision disorder characterized by reduced visual acuity in one eye. Traditional treatments include patching or atropine penalization of the dominant eye to stimulate the weaker eye. CureSight offers a novel digital approach by combining eye-tracking technology with streamed content and anaglyph glasses to engage children in therapy. This method targets patients with best-corrected visual acuity of 20/100 or better and mild strabismus (≤5 prism diopters).

Data Highlights

CureSight treatment involves a recommended 30 hours per 30-day cycle, with a typical treatment duration of at least 6 months. Follow-up visits are recommended every 3 months and can be billed under CPT codes 92012, 0704T, 0705T, and 0706T depending on the service. Improvements have been noted in visual acuity, Randot stereotesting, and Worth 4 Dot testing, indicating enhanced binocular function.

Key Findings

• CureSight selectively blurs the dominant eye's central vision while providing a sharp image to the amblyopic eye, promoting its use.
• The platform is FDA-approved for children aged 4 to 9 with anisometropic and mild strabismic amblyopia and best-corrected VA of 20/100 or better.
• Eye-tracking technology monitors gaze position during streaming content, enhancing patient engagement and adherence.
• Follow-up intervals are recommended every 90 days, with remote monitoring and adherence tracking facilitated by CPT codes 0706T and others.
• Clinical users report improvements in visual acuity, stereoacuity, and binocular function tests such as Randot and Worth 4 Dot.
• CureSight is contraindicated in patients with light-induced epilepsy and may be less suitable for children with limited attention spans or parental concerns about screen time.

Clinical Implications

CureSight offers an engaging, technology-driven alternative to traditional patching, potentially improving adherence and outcomes in pediatric amblyopia treatment. Its remote monitoring capabilities allow for efficient follow-up and adherence tracking. Clinicians should consider patient suitability, including attention span and epilepsy history, when prescribing this therapy.

Conclusion

Digital patching with CureSight represents a promising advancement in amblyopia management, combining patient engagement with objective monitoring to improve visual and binocular outcomes in young children. Early clinical experiences support its use as a first-line or adjunctive therapy.

References

1. NovaSight -- CureSight Digital Amblyopia Treatment Platform
2. Wesley Cox, OD -- Clinical Experience with CureSight
3. Carly Kiomall, OD, MPH, FAAO -- Monitoring and Billing for CureSight
4. Elizabeth Bennett, OD, FAAO -- First-line Use of CureSight